TABLE 3.
Univariate analysis of clinical features associated with inpatient mortality
| Parametera | Value for the group |
P value | |
|---|---|---|---|
| Nonsurvivors (n = 27) | Survivors (n = 60) | ||
| Median (IQR) age (yr) | 65.0 (56.0–80.0) | 59.0 (56.0–80.0) | 0.132 |
| Median SOFA score (IQR) | 8 (6–9) | 5 (3–7) | 0.001 |
| Median Charlson score (IQR) | 6 (4–7) | 5 (2–7) | 0.115 |
| No. (%) of female patients | 8 (29.6) | 26 (43.3) | 0.226 |
| Clinical factors (no. of patients [%]) | |||
| Diabetes | 10 (37.0) | 22 (36.7) | 0.974 |
| History of CVA | 7 (25.9) | 16 (26.7) | 0.942 |
| Any respiratory pathology | 14 (51.9) | 26 (43.3) | 0.635 |
| HIV/AIDS | 2 (7.4) | 3 (5.0) | 0.655 |
| Liver disease | 3 (11.1) | 6 (10.0) | 0.875 |
| Intravenous drug use | 6 (22.2) | 13 (21.7) | 0.952 |
| Acute kidney injury | 8 (29.6) | 31 (51.7) | 0.152 |
| Hemodialysis | 1 (3.7) | 6 (10.0) | 0.318 |
| No. (%) of patients with prior hospitalization | 11 (40.7) | 36 (60.0) | 0.095 |
| Antibiotic use in the last 30 days (no. of patients [%]) | 2 (7.4) | 11 (18.3) | 0.396 |
| Previous vancomycin treatment (30 days) | 2 (7.4) | 10 (16.7) | 0.247 |
| Vancomycin therapy (no. of patients [%]) | |||
| Vancomycin trough of <15 mg/liter | 11 (45.8) | 31 (57.4) | 0.344 |
| No change in antibiotic therapy | 14 (51.9) | 39 (65.0) | 0.245 |
| ID consult (no. of patients [%]) | 11 (40.7) | 40 (66.7) | 0.023 |
| Concurrent bacteremia (no. of patients [%]) | 25 (92.6) | 54 (90.0) | 0.207 |
| Median (IQR) duration of bacteremia (days) | 3 (1–6) | 2 (1–5) | 0.717 |
| Presence of concurrent sites of infection (no. of patients [%]) | |||
| Skin/soft tissue | 4 (14.8) | 11 (18.3) | 0.688 |
| Deep abscess | 0 (0.0) | 1 (1.7) | 0.500 |
| Infective endocarditis | 2 (7.4) | 2 (3.3) | 0.401 |
| Bone/joint | 1 (3.7) | 2 (3.3) | 0.930 |
| Unknown | 4 (14.8) | 8 (13.3) | 0.853 |
| ICU admission (no. of patients [%]) | 23 (85.2) | 41 (63.8) | 0.099 |
| No. (%) of patients receiving mechanical ventilation (any) | 21 (77.8) | 34 (56.7) | 0.059 |
| Presence of other respiratory pathogens (no. of patients [%]) | |||
| Acinetobacter spp. | 4 (14.8) | 7 (11.7) | 0.683 |
| Pseudomonas spp. | 2 (7.4) | 8 (13.3) | 0.423 |
| Klebsiella spp. | 0 (0.0) | 8 (13.3) | 0.046 |
| Streptococcal spp. | 1 (3.7) | 8 (8.3) | 0.430 |
| Presence of MRSA isolate type (no. of patients [%]) | |||
| hVISA phenotype | 13 (48.1) | 14 (23.3) | 0.049 |
| VAN MIC of 2 mg/liter (BMD) | 4 (15.4) | 5 (8.8) | 0.501 |
| SCCmec type II | 13 (48.1) | 30 (50.0) | 0.873 |
| PVL positive | 13 (48.1) | 10 (16.7) | 0.002 |
| USA300 | 8 (29.6) | 14 (23.3) | 0.532 |
| agr type II | 14 (51.9) | 27 (45.0) | 0.554 |
| agr dysfunction | 8 (29.6) | 23 (38.3) | 0.433 |
a
IQR, interquartile range; SOFA, sequential organ failure assessment; CVA, cerebrovascular accident; HIV, human immunodeficiency virus; MRSA, methicillin-resistant S. aureus; hVISA, heterogeneous vancomycin-intermediate S. aureus.